NEWCELX LTD
NCELNASDAQ🏆 #5405 by market capEarnings Mar 3US Equity
$3.00▼ $0.17 (−5.66%)
LiveTrack NCEL
Get earnings, price moves & breaking news on Telegram
24h▼ 5.7%
7d▲ 0.0%
14d▼ 10.6%
30d▼ 9.1%
ytd▲ 47.8%
1y▼ 87.8%
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
76
Good
Trading Snapshot
- Day Range
- $2.96 – $3.01
- 52-Week Range
- $1.83 – $24.60
- Volume
- $1.65B
- Avg Volume
- $2.01B
- Shares Outstanding
- 450,000
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $136,364
- Last Q Revenue
- $34,171
- P/E Ratio
- 8.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $0.25
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.0%
Why Investors Own NCEL
- ✓High-growth profile — revenue up +20.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEWCELX LTD
NCELFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$2M▼ −43.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −35.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.4M▲ +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▲ +$181K YoY
StockOtter · stockotter.spaceAbout NEWCELX LTD
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026
Latest News & Updates
🚀
CNBC·2h ago
NEWCELX LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift NCEL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
NEWCELX LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.